UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 36

Sortiert nach

Circulating tumor cells in locally advanced pancreatic adenocarcinoma: the ancillary CirCe 07 study to the LAP 07 trial

Annals of oncology, 2013-08, Vol.24 (8), p.2057-2061

2013

Link zum Volltext

Verfügbarkeit prüfen

Circulating tumor cell thresholds and survival scores in advanced metastatic breast cancer: The observational step of the CirCe01 phase III trial

Cancer letters, 2015-05, Vol.360 (2), p.213-218

2015

Link zum Volltext

Verfügbarkeit prüfen

SP-0572: Circulating tumour DNA, a new tool for the early detection of poor outcome

Radiotherapy and oncology, 2017-05, Vol.123, p.S304-S304

Bidard, F.C.

2017

Link zum Volltext

Verfügbarkeit prüfen

Disseminated and circulating tumor cells in gastrointestinal oncology

Critical reviews in oncology/hematology, 2012-05, Vol.82 (2), p.103-115

2012

Link zum Volltext

Verfügbarkeit prüfen

281 Quantitative Assessment of Her-2 Expression of Circulating Tumor Cells in Patients with Metastatic and Non Metastatic Breast Cancer

European journal of cancer (1990), 2012-03, Vol.48, p.S124-S125

2012

Link zum Volltext

Verfügbarkeit prüfen

2772 Circulating tumor cells kinetics in ovarian carcinoma: correlation with baseline characteristics and CA-125 levels in the randomized ANTHALYA trial evaluating bevacizumab in the neoadjuvant setting

European journal of cancer (1990), 2015-09, Vol.51, p.S555-S555

2015

Link zum Volltext

Verfügbarkeit prüfen

Circulating tumor cell detection and transcriptomic profiles in early breast cancer patients

Annals of oncology, 2011-06, Vol.22 (6), p.1458-1459

2011

Link zum Volltext

Verfügbarkeit prüfen

Validation over time of a nomogram including HER2 status to predict the sentinel node positivity in early breast carcinoma

European journal of surgical oncology, 2012-12, Vol.38 (12), p.1211-1217

2012

Link zum Volltext

Verfügbarkeit prüfen

A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1)

Annals of oncology, 2016-05, Vol.27 (5), p.812-818

2016

Link zum Volltext

Verfügbarkeit prüfen

353 Assessment of Circulating Tumor Cells and Serum Markers for Progression-free Survival Prediction in Metastatic Breast Cancer: a Prospective Observational Study

European journal of cancer (1990), 2012-03, Vol.48, p.S146-S146

2012

Link zum Volltext

Verfügbarkeit prüfen

5023 POSTER DISCUSSION Cyfra 21-1 Correlation With Circulating Tumour Cells (CTC) Detection and Patient Outcome in Metastatic Breast Cancer: Results of a Substudy of the Prospective IC 2004-06 Trial

European journal of cancer (1990), 2011, Vol.47, p.S337-S337

2011

Link zum Volltext

Verfügbarkeit prüfen

1181TiP BEPCOME-MB: Treatment of BRAFV600 mutated melanoma brain metastases with encorafenib + binimetinb + pembrolizumab with or without stereotactic radiosurgery

Annals of oncology, 2023-10, Vol.34, p.S700-S700

2023

Link zum Volltext

Verfügbarkeit prüfen

Survival of breast cancer patients with meningeal carcinomatosis

Annals of oncology, 2010-11, Vol.21 (11), p.2183-2187

2010

Link zum Volltext

Verfügbarkeit prüfen

Long-Term Impact of Bone Marrow Disseminated Tumor Cells Detection of Breast Cancer Locoregional Relapses

International journal of radiation oncology, biology, physics, 2017-10, Vol.99 (2), p.S55-S56

2017

Link zum Volltext

Verfügbarkeit prüfen

113P Efficacy of oral etoposide associated with trastuzumab in HER2-positive metastatic breast cancer: Results from the Institut Curie’s database

Annals of oncology, 2021-05, Vol.32, p.S71

2021

Link zum Volltext

Verfügbarkeit prüfen

5MO Hypomethylation of circulating retrotransposons: Towards a non-invasive pan-cancer diagnosis

Annals of oncology, 2022-10, Vol.33, p.S1385-S1385

2022

Link zum Volltext

Verfügbarkeit prüfen

273P A preoperative window-of-opportunity (WOO) study of imlunestrant in ER+, HER2- early breast cancer (EBC): Final analysis from EMBER-2

Annals of oncology, 2023-10, Vol.34, p.S292-S293

2023

Link zum Volltext

Verfügbarkeit prüfen

188O EMERALD trial analysis of patient-reported outcomes (PROs) in patients with ER+/HER2− advanced or metastatic breast cancer (mBC) comparing oral elacestrant vs standard of care (SoC) endocrine therapy

ESMO open, 2023-05, Vol.8 (1), p.101377, Article 101377

2023

Link zum Volltext

Verfügbarkeit prüfen

Clinicopathological characteristics, survival and prognostic factors of breast cancer-related microangiopathic haemolytic anemia: A multicenter study

Annals of oncology, 2019-10, Vol.30, p.v134

2019

Link zum Volltext

Verfügbarkeit prüfen

368P - Clinicopathological characteristics, survival and prognostic factors of breast cancer-related microangiopathic haemolytic anemia: A multicenter study

Annals of oncology, 2019-10, Vol.30, p.v134-v134

2019

Link zum Volltext

Verfügbarkeit prüfen

869P Prognostic impact of HPV ctDNA detection during chemoradiotherapy for cervix carcinoma

Annals of oncology, 2020-09, Vol.31, p.S641-S641

2020

Link zum Volltext

Verfügbarkeit prüfen

30P E-cadherin inactivation shapes tumor microenvironment specificities in invasive lobular carcinoma

ESMO open, 2024-05, Vol.9, p.103038, Article 103038

2024

Link zum Volltext

Verfügbarkeit prüfen

51P ctDNA analyses at baseline in patients with ER-positive (ER+), HER2-negative (HER2-) advanced breast cancer (aBC) treated with imlunestrant in the EMBER phase I study

ESMO open, 2024-05, Vol.9, p.103058, Article 103058

2024

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 36

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(36)
Mit Volltextzugriff
(36)

Publikationsform

Artikel
(36)

Sprache

Englisch
(36)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Hematology, Oncology And Palliative Medicine
(8)
Humans
(8)
Life Sciences & Biomedicine
(8)
Oncology
(8)
Science & Technology
(8)
Female
(7)
Middle Aged
(6)
Aged
(4)
Biological And Medical Sciences
(4)
Disease-Free Survival
(4)
Medical Sciences
(4)
Tumors
(4)
Adult
(3)
Antineoplastic Agents
(3)
Breast Cancer
(3)
Circulating Tumor Cells
(3)
Gastroenterology. Liver. Pancreas. Abdomen
(3)
Life Sciences
(3)
Pharmacology. Drug Treatments
(3)
Survival Rate
(3)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

EZB Electronic Journals Library
(26)
Journals@Ovid Complete
(21)
Ingenta E-Journals
(14)
Elsevier ScienceDirect Journals Complete
(11)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(9)
IngentaConnect Journals
(9)
MEDLINE
(8)

2 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Circulating tumor cells in locally advanced pancreatic adenocarcinoma: the ancillary CirCe 07 study to the LAP 07 trial

Circulating tumor cell thresholds and survival scores in advanced metastatic breast cancer: The observational step of the CirCe01 phase III trial

SP-0572: Circulating tumour DNA, a new tool for the early detection of poor outcome

Disseminated and circulating tumor cells in gastrointestinal oncology

281 Quantitative Assessment of Her-2 Expression of Circulating Tumor Cells in Patients with Metastatic and Non Metastatic Breast Cancer

2772 Circulating tumor cells kinetics in ovarian carcinoma: correlation with baseline characteristics and CA-125 levels in the randomized ANTHALYA trial evaluating bevacizumab in the neoadjuvant setting

Circulating tumor cell detection and transcriptomic profiles in early breast cancer patients

Validation over time of a nomogram including HER2 status to predict the sentinel node positivity in early breast carcinoma

A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1)

353 Assessment of Circulating Tumor Cells and Serum Markers for Progression-free Survival Prediction in Metastatic Breast Cancer: a Prospective Observational Study

5023 POSTER DISCUSSION Cyfra 21-1 Correlation With Circulating Tumour Cells (CTC) Detection and Patient Outcome in Metastatic Breast Cancer: Results of a Substudy of the Prospective IC 2004-06 Trial

1181TiP BEPCOME-MB: Treatment of BRAFV600 mutated melanoma brain metastases with encorafenib + binimetinb + pembrolizumab with or without stereotactic radiosurgery

Survival of breast cancer patients with meningeal carcinomatosis

Long-Term Impact of Bone Marrow Disseminated Tumor Cells Detection of Breast Cancer Locoregional Relapses

113P Efficacy of oral etoposide associated with trastuzumab in HER2-positive metastatic breast cancer: Results from the Institut Curie’s database

5MO Hypomethylation of circulating retrotransposons: Towards a non-invasive pan-cancer diagnosis

220P Elacestrant vs fulvestrant or aromatase inhibitor (AI) in phase III trial evaluating elacestrant, an oral selective estrogen receptor degrader (SERD), vs standard of care (SOC) endocrine monotherapy for ER+/HER2- advanced/metastatic breast cancer (mBC): Subgroup analysis from EMERALD

273P A preoperative window-of-opportunity (WOO) study of imlunestrant in ER+, HER2- early breast cancer (EBC): Final analysis from EMBER-2

188O EMERALD trial analysis of patient-reported outcomes (PROs) in patients with ER+/HER2− advanced or metastatic breast cancer (mBC) comparing oral elacestrant vs standard of care (SoC) endocrine therapy

Clinicopathological characteristics, survival and prognostic factors of breast cancer-related microangiopathic haemolytic anemia: A multicenter study

368P - Clinicopathological characteristics, survival and prognostic factors of breast cancer-related microangiopathic haemolytic anemia: A multicenter study

167MO Association between ER, PR and HER2 levels and outcome under palbociclib (Pal) + aromatase inhibitors (AIs) as first-line therapy for ER+ HER2- metastatic breast cancer (MBC): An exploratory analysis of the PADA-1 trial

869P Prognostic impact of HPV ctDNA detection during chemoradiotherapy for cervix carcinoma

30P E-cadherin inactivation shapes tumor microenvironment specificities in invasive lobular carcinoma

51P ctDNA analyses at baseline in patients with ER-positive (ER+), HER2-negative (HER2-) advanced breast cancer (aBC) treated with imlunestrant in the EMBER phase I study

Suchergebnisse filtern